FindTrial
Sign In

BPH and cancer of prostate

Role of serum ferritin and serum PSA levels in Benign Prostatic Hypertrophy and Carcinoma Prostate

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/10/046786
Enrollment
42
Registered
2022-10-26
Start date
Unknown
Completion date
Unknown
Last updated
2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C61- Malignant neoplasm of prostate

Interventions

None listed

Sponsors

Rohilkhand Medical College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Clinically suspected cases of BPH and carcinoma prostate in whom biopsy will be performed.

Exclusion criteria

Exclusion criteria: Biopsies showing evidence of associated marked inflammation. Patients with established systemic inflammatory conditions or on treatment. Patients with any other associated malignancy.

Design outcomes

Primary

MeasureTime frame
comparison between serum ferritin and serum PSA levels in benign prostatic hyperplasiaTimepoint: Per-operative samples taken—

Secondary

MeasureTime frame
to see serum ferritin and serum PSA levels in carcinoma prostate and correlating with histology reports.Timepoint: pre-operative samples taken—

Countries

India

Contacts

Public ContactMithila Bisht

Rohilkhand medical college and hospital, Bareilly.

dr.mithilapathologist@gmail.com7906080213

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026